生物
滤泡性淋巴瘤
淋巴瘤
追踪
计算生物学
癌症研究
遗传学
免疫学
计算机科学
操作系统
作者
Joseph G. Schroers‐Martin,Joanne Soo,Gabriel Brisou,Florian Scherer,David M. Kurtz,Brian J. Sworder,Michael S. Khodadoust,Michael C. Jin,Agnès Bru,Chih Long Liu,Henning Stehr,Paolo Vineis,Yasodha Natkunam,Lauren R. Teras,Joo Y. Song,Bertrand Nadel,Maximilian Diehn,Sandrine Roulland,Ash A. Alizadeh
出处
期刊:Cancer Discovery
[American Association for Cancer Research]
日期:2023-03-20
卷期号:13 (6): 1310-1323
被引量:21
标识
DOI:10.1158/2159-8290.cd-23-0111
摘要
Follicular lymphomas (FL) are characterized by BCL2 translocations, often detectable in blood years before FL diagnosis, but also observed in aging healthy individuals, suggesting additional lesions are required for lymphomagenesis. We directly characterized early cooperating mutations by ultradeep sequencing of prediagnostic blood and tissue specimens from 48 subjects who ultimately developed FL. Strikingly, CREBBP lysine acetyltransferase (KAT) domain mutations were the most commonly observed precursor lesions, and largely distinguished patients developing FL (14/48, 29%) from healthy adults with or without detected BCL2 rearrangements (0/13, P = 0.03 and 0/20, P = 0.007, respectively). CREBBP variants were detectable a median of 5.8 years before FL diagnosis, were clonally selected in FL tumors, and appeared restricted to the committed B-cell lineage. These results suggest that mutations affecting the CREBBP KAT domain are common lesions in FL cancer precursor cells (CPC), with the potential for discriminating subjects at risk of developing FL or monitoring residual disease.Our study provides direct evidence for recurrent genetic aberrations preceding FL diagnosis, revealing the combination of BCL2 translocation with CREBBP KAT domain mutations as characteristic committed lesions of FL CPCs. Such prediagnostic mutations are detectable years before clinical diagnosis and may help discriminate individuals at risk for lymphoma development. This article is highlighted in the In This Issue feature, p. 1275.
科研通智能强力驱动
Strongly Powered by AbleSci AI